Is there a link between oestrogen therapy and gallbladder disease?

Area of Science:

• Endocrinology
• Gastroenterology
• Epidemiology

Background:

• Cholelithiasis (gallstones) is a prevalent benign gallbladder disease with significant healthcare costs.
• Female sex hormones are causally linked to cholesterol gallstone formation, explaining higher prevalence in women.
• Pregnancy and exogenous hormone use, including oral contraceptives and hormone replacement therapy (HRT), elevate cholelithiasis risk.

Purpose of the Study:

• To evaluate the causal relationship between estrogen use and gallbladder disease.
• To determine the influence of progestins on estrogen-induced gallbladder disease risk.
• To provide evidence-based recommendations for HRT prescribing in relation to gallbladder disease.

Main Methods:

• Analysis of findings from two randomized controlled trials: the Heart and Estrogen/Progestin Replacement Study and the Women's Health Initiative postmenopausal hormone trial.
• Investigating the association between oral estrogen use and gallbladder disease in postmenopausal women.
• Assessing the impact of progestin co-administration on this association.

Main Results:

• Oral estrogen use in postmenopausal women is unequivocally causally associated with gallbladder disease.
• The presence or absence of progestins does not significantly alter the magnitude of this estrogen effect.
• Oral contraceptives were not found to pose a greater risk for gallbladder disease.

Conclusions:

• Postmenopausal estrogen therapy significantly increases the risk of gallbladder disease.
• HRT should be prescribed cautiously, using the lowest effective dose for the shortest duration.
• Women with asymptomatic gallstones should avoid estrogen therapy to prevent cholecystitis.